Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma

NCT03086993 is registered in ClinicalTrials.gov with Delcath Systems Inc. as lead sponsor.

NCT NCT03086993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03086993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma
Lead sponsor
Delcath Systems Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
April 10, 2018
Completion date
May 31, 2023
Enrollment
295 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, intrahepatic cholangiocarcinoma